A detailed history of Horizon Kinetics Asset Management LLC transactions in Biogen Inc. stock. As of the latest transaction made, Horizon Kinetics Asset Management LLC holds 3,121 shares of BIIB stock, worth $542,804. This represents 0.01% of its overall portfolio holdings.

Number of Shares
3,121
Previous 3,121 -0.0%
Holding current value
$542,804
Previous $672,000 7.59%
% of portfolio
0.01%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

BUY
$212.02 - $267.71 $424 - $535
2 Added 0.06%
3,121 $672,000
Q4 2023

Feb 15, 2024

SELL
$222.59 - $267.94 $29,159 - $35,100
-131 Reduced 4.03%
3,119 $807,000
Q1 2023

May 12, 2023

SELL
$256.56 - $292.34 $128,280 - $146,170
-500 Reduced 13.33%
3,250 $903,000
Q4 2021

Feb 15, 2022

SELL
$223.92 - $287.77 $27,990 - $35,971
-125 Reduced 3.23%
3,750 $900,000
Q2 2021

Aug 16, 2021

SELL
$259.0 - $414.71 $12,950 - $20,735
-50 Reduced 1.27%
3,875 $1.34 Million
Q1 2021

May 11, 2021

SELL
$242.95 - $284.63 $7,045 - $8,254
-29 Reduced 0.73%
3,925 $1.1 Million
Q4 2020

Feb 16, 2021

SELL
$236.26 - $355.63 $10,631 - $16,003
-45 Reduced 1.13%
3,954 $968,000
Q2 2020

Aug 14, 2020

SELL
$258.66 - $342.55 $32,332 - $42,818
-125 Reduced 3.03%
3,999 $1.07 Million
Q1 2020

May 13, 2020

SELL
$268.85 - $341.04 $34,950 - $44,335
-130 Reduced 3.06%
4,124 $1.31 Million
Q4 2019

Feb 14, 2020

SELL
$220.06 - $304.07 $60,516 - $83,619
-275 Reduced 6.07%
4,254 $1.26 Million
Q3 2019

Nov 14, 2019

SELL
$217.44 - $243.88 $21,744 - $24,388
-100 Reduced 2.16%
4,529 $1.05 Million
Q2 2019

Aug 14, 2019

BUY
$219.29 - $241.72 $27,411 - $30,215
125 Added 2.78%
4,629 $1.08 Million
Q1 2019

May 15, 2019

BUY
$216.71 - $338.96 $976,061 - $1.53 Million
4,504 New
4,504 $1.07 Million

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $25B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Horizon Kinetics Asset Management LLC Portfolio

Follow Horizon Kinetics Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Horizon Kinetics Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Horizon Kinetics Asset Management LLC with notifications on news.